Epilepsy
Conditions
Keywords
epilepsy, autoimmune antibody, diagnose
Brief summary
multi-central and prospectively study the diagnostic value of autoimmune antibody detection in new and chronic epilepsy, and provide reference for clinical practice
Detailed description
multi-centrally recruit patients with newly onset or chronic epilepsy and hoping to find whether there exist an autoimmune cause. whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom. At 3 and 6 months later, all patients will be followed-up, and the positive autoimmune antibody will be redetected. the clinical manifest, clinical data, medication and treatment outcome will be recorded and analyzed, to study the diagnostic value of autoimmune antibody detection in new and chronic epilepsy
Interventions
None listed
Sponsors
General Hospital of Ningxia Medical University
LanZhou University
First Affiliated Hospital, Sun Yat-Sen University
Henan Provincial People's Hospital
The Affiliated Hospital of Inner Mongolia Medical University
First Affiliated Hospital of Zhejiang University
Wulumuqi General Hospital of Lanzhou Military Command
Xuanwu Hospital, Beijing
Xiangya Hospital of Central South University
West China Hospital
Affiliated Hospital of Qinghai University
Xijing Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients diagnosed with epilepsy according to the diagnostic criteria of International League Against Epilepsy (ILAE) 2017 * Age from 16 to 70 years old * The etiology of patients with epilepsy is unknown * The patient or guardian signs an informed consent and can cooperate with the inspection and follow-up for six months
Exclusion criteria
* Patients with hereditary, infectious, and metabolic epilepsy * The investigation and follow-up cannot be completed due to vision, hearing, language expression, disturbance of consciousness, and impaired understanding, and the guardian cannot replace the completed * Patients with other progressive or systemic diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change of the seizure frequency | at six months after the patients being enrolled | Seizure frequency are described as no seizures, less than one per month, monthly, weekly, and daily. the change of seizure frequency include 'increased', 'decreased', and 'no change' compared to the frequency before they were enrolled |
| change of the autoimmune antigen | at six months after the patients being enrolled | autoimmune antigen in the serum of patients was described as positive and negative. the change of the autoimmune antigen include 'turn negative' and 'still positive' compared to the first detection. |
Outcome results
None listed